| http://www.w3.org/ns/prov#value | - Efficacy can be determined in association with any known method for diagnosing, identifying, or treating a triple negative breast cancer.The present invention also comprises a kit with a detection reagent that binds to two or more of the TNBCMARKERS proteins, nucleic acids, polymorphisms, metabolites, or other analytes.
|
